openPR Logo
Press release

Primary Immunodeficiency Market Size is Anticipated to Boosting at a CAGR of ~6 % by 2028 | Transparency Market Research

03-15-2024 09:34 AM CET | Health & Medicine

Press release from: Transparency Market Research

Primary Immunodeficiency Market Size is Anticipated

The Primary Immunodeficiency Market is driven by several factors, including advances in genetic testing and diagnostics, increased awareness and recognition of PIDs, growing research and development efforts, and the availability of targeted therapies and supportive treatments. PIDs encompass a wide range of disorders, including antibody deficiencies, cellular immunodeficiencies, complement deficiencies, and innate immune disorders, each requiring specific management strategies tailored to the underlying immune defect.

Primary Immunodeficiency market is estimated to attain a valuation of ~US$ 9.9 Bn by the end of 2028, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of ~6% during the forecast period, 2020-2028

Get a Sample Copy of the Primary Immunodeficiency Market Research Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137&utm_source=openpr_amitugare&utm_medium=openpr

The significant players operating in the global Primary Immunodeficiency market are

Shire plc, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A, Octapharma

Key Drivers of the Primary Immunodeficiency Market:

Advances in Genetic Testing and Diagnosis: Improvements in genetic testing technologies, next-generation sequencing (NGS), and molecular diagnostics enable early and accurate diagnosis of PIDs, facilitating personalized treatment approaches and improving patient outcomes.

Increased Awareness and Recognition: Heightened awareness among healthcare providers, patients, and the general public about PIDs contributes to earlier recognition, referral, and management of immune deficiency disorders, reducing diagnostic delays and improving access to care.

Research and Development: Ongoing research efforts focus on elucidating the underlying mechanisms of PIDs, identifying novel genetic mutations, and developing targeted therapies, gene therapies, and immunomodulatory agents to address specific immune defects and improve immune function.

Therapeutic Advances: The development and commercialization of therapeutic interventions for PIDs, including immunoglobulin replacement therapy, hematopoietic stem cell transplantation (HSCT), gene therapy, cytokine therapy, and small molecule inhibitors, offer new treatment options and improved outcomes for patients with primary immunodeficiencies.

Patient Advocacy and Support: Patient advocacy organizations, support groups, and online communities play a vital role in raising awareness, providing education, advocating for access to care, and offering support services for individuals and families affected by PIDs, enhancing quality of life and promoting patient empowerment.

Recent Developments in the Primary Immunodeficiency Market:

Introduction of novel therapeutic modalities for PIDs, including gene therapy approaches, targeted biologics, and small molecule inhibitors, aimed at correcting underlying immune defects, modulating immune function, and preventing infections and complications.
Expansion of newborn screening programs and diagnostic algorithms for PIDs, enabling early identification and intervention in asymptomatic or presymptomatic individuals, reducing the risk of severe infections and long-term complications.
Implementation of precision medicine approaches in the management of PIDs, incorporating genetic testing, immune profiling, and personalized treatment strategies based on individual patient characteristics, immune phenotype, and disease severity.
Integration of digital health technologies, telemedicine platforms, and remote monitoring tools into PID care delivery models to improve access to specialized care, facilitate patient-provider communication, and enhance disease management and treatment adherence.
Collaboration among stakeholders in academia, industry, government agencies, and patient advocacy groups to advance research, clinical trials, and public health initiatives aimed at improving diagnosis, treatment, and outcomes for individuals with primary immunodeficiencies.

Buy this Premium Research Report: - https://www.transparencymarketresearch.com/checkout.php?rep_id=3137<ype=S

Market Segmentation -

Type

Antibody Deficiency
Agammaglobulinaemia
Common Variable Immune Deficiency
Selective IgA Deficiency
IgG Subclass Deficiency
Others
Cellular Deficiency
Ataxia Telangiectasia
Hyper IgM Syndromes
Wiskott-Aldrich Syndrome
DiGeorge Syndrome
Others
Innate Immune
Complement Deficiencies
Hyper IgE Syndrome
Others

End User

Immunoglobuline Replacement Therapy
Antibiotic Therapy
Stem Cell and Gene Therapy
Others (Vaccines, Nutritional Supplements, and Others)
This Report lets you identify the opportunities in Primary Immunodeficiency Market by means of a region:

North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

Key Features of the Primary Immunodeficiency Market Report: -

➤ Analyze competitive developments such as expansions, deployments, new product launches, and market acquisitions.

➤ Examine the market opportunities for stakeholders by identifying higher growth sections.

➤ To study and analyze the global Primary Immunodeficiency industry status and forecast including key regions.

➤ An in-depth analysis of key product segments and application spectrum, providing strategic recommendations to incumbents and new entrants to give them a competitive advantage over others.

➤ It provides a comprehensive analysis of key regions of the industry as well as a SWOT analysis and Porter's Five Forces analysis to provide a deeper understanding of the market.

➤ It helps you make strategic business decisions and investment plans.

More Trending Reports by Transparency Market Research -

Smoking Cessation and Nicotine De Addiction Market: https://www.globenewswire.com/en/news-release/2024/03/11/2843670/32656/en/Smoking-Cessation-and-Nicotine-De-Addiction-Market-to-Reach-USD-27-84-billion-by-2031-at-a-CAGR-of-10-2-Transparency-Market-Research-Inc.html

Dental Suction Mirror Market: https://www.globenewswire.com/en/news-release/2024/03/11/2843924/32656/en/Dental-Suction-Mirror-Market-Poised-to-Grow-to-USD-79-2-million-by-2031-With-a-4-8-CAGR-Exclusive-Report-by-Transparency-Market-Research-Inc.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Immunodeficiency Market Size is Anticipated to Boosting at a CAGR of ~6 % by 2028 | Transparency Market Research here

News-ID: 3431416 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Primary

Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025:  …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market. Description The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries". The Global Primary Cells
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
01-25-2017 | Health & Medicine
TMR
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes